International Journal of Gynecological Cancer

Papers
(The H4-Index of International Journal of Gynecological Cancer is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma1035
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*138
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer98
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-174
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors69
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program68
Human papillomavirus-independent cervical cancer60
Evaluating meaningful levels of financial toxicity in gynecologic cancers57
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery56
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer55
Management of pregnancy in women with cancer54
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 202352
Uterine serous carcinoma: key advances and novel treatment approaches47
Advances in immunotherapy for cervical cancer: recent developments and future directions46
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment follo44
SUCCOR cone study: conization before radical hysterectomy42
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification42
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-00140
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer38
Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management37
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)33
Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer32
Ultrastaging methods of sentinel lymph nodes in endometrial cancer – a systematic review30
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?29
Endometrial carcinosarcoma29
Imaging modalities in pregnant cancer patients28
Updates in the treatment of vaginal cancer27
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis27
0.039661884307861